LyGenesis, a Pittsburgh, PA-based clinical-stage biotechnology company, raised $19M in Series A-2 funding.
The round was led by Prime Movers Lab, with participation form Juvenescence. Justin Briggs, Biologist and Partner at Prime Movers Lab, who will be joining LyGenesis’s Board of Directors.
The company intends to use the funds to complete its Phase 2a clinical trial (ClinicalTrials.gov Identifier: NCT04496479) and advance its pipeline of cell therapies.
LyGenesis is a clinical-stage biotechnology company whose cell therapies use patients’ lymph nodes as bioreactors to regrow functioning ectopic organs. Its lead allogeneic cell therapy program is currently in a Phase 2a clinical trial for patients with end stage liver disease (ClinicalTrials.gov Identifier: NCT04496479). LyGenesis’s drug development pipeline includes cell therapies that can produce an ectopic thymus (for aging and multiple other potential indications), pancreas (for Type 1 diabetes), and kidney (for end stage renal disease).
FinSMEs
24/10/2023